The European Commission informed the Board about its legal proposals to revise the pharmaceutical legislation, published on 26 April, which aim to make the EU regulatory framework fit for innovative medicines, support greater access to medicines for patients and better address major public health challenges of the future.
The Board was updated on EMA’s response to COVID-19. Following the end of the public health emergencies of international concern (PHEIC) being declared by WHO for COVID-19 and mpox in May 2023, some of the activities that EMA implemented during the pandemic are being rolled back to focus on preparedness for future crises. The COVID-19 business continuity plans for EMA and the European medicines regulatory network were also lifted on 10 May (see news announcement here).
The Board acknowledged the crucial role EMA and the European medicines regulatory network played during the pandemic and the transformation the Agency underwent during that period in terms of its regulatory responsibilities…
